A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone

Mamatha Karanth, Suparno Chakrabarti, Richard Lovell, C Harvey, K Holder, Christopher McConkey, D McDonald, Christopher Fegan, Donald Milligan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We conducted a prospective randomised study to compare the efficiency of out-patient progenitor cell mobilisation using either intermediate-dose cyclophosphamide (2 g/m(2)) and lenograstim at 5 micrograms/kg (Cyclo-G-CSF group, n=39) or lenograstim alone at 10 micrograms/kg (G-CSF group, n=40). The end points were to compare the impact of the two regimens on mobilisation efficiency, morbidity, time spent in hospital, the number of apheresis procedures required and engraftment kinetics. Successful mobilisation was achieved in 28/40 (70%) in the G-CSF group vs 22/39 (56.4%) for Cyclo-G-CSF (P=0.21). The median number of CD34+ cells mobilised was 2.3 x 10(6)/kg and 2.2 x 10(6)/kg for G-CSF and cyclo-G-CSF arms following a median of two apheresis procedures. Nausea and vomiting and total time spent in the hospital during mobilisation were significantly greater after Cyclo-G-CSF (P
Original languageEnglish
Pages (from-to)399-403
Number of pages5
JournalBone Marrow Transplantation
Volume34
Early online date26 Jul 2004
DOIs
Publication statusPublished - 26 Jul 2004

Keywords

  • cyclophosphamide
  • lenograstim
  • PBPC mobilization

Fingerprint

Dive into the research topics of 'A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone'. Together they form a unique fingerprint.

Cite this